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Further studies are needed to better under-
stand the impact of alitretinoin in LP. Our ob-
servation suggests alitretinoin as a new, well-
tolerated treatment option for esophage-
al LP after failed response to conventional 
treatments.  © 2013 S. Karger AG, Basel 
 Case 
 We present the case of a 54-year-old 
woman suffering from purple, polygonal 
papules in a longitudinal configuration on 
the right medial thigh and whitish lacy 
patches of the oral buccal mucosa ( fig. 1 a). 
She complained about gradually increasing 
pruritus and burning sensation of the skin 
and mucosal lesions. The vulvovaginal area 
was uninvolved. Histology of the buccal 
mucosa revealed lichenoid skin inflamma-
tion ( fig. 2 ). HIV, hepatitis B/C serologies, 
bacterial and fungal smears as well as lab-
oratory investigations such as transami-
nases, creatinine and differential blood 
counts were inconspicuous. The diagnosis 
of oral and cutaneous lichen ruber planus 
was made.
 After intramuscular injection of 40 mg 
triamcinolone acetonide, the skin changes 
resolved but the oral lesions expanded to 
the tongue and the patient developed dys-
 Key Words 
 Oral lichen planus · Esophageal lichen 
planus · Cutaneous lichen planus · Lichen 
ruber planus · Alitretinoin 
 Abstract 
 Background: Therapy-resistant lichen pla-
nus (LP) can be a challenging condition for 
dermatologists. There are some case reports 
about successful treatments with alitretinoin 
of cutaneous and oral, but not of esophageal 
LP.  Objective: We present the unique case of 
a patient with cutaneous, oral and esoph-
ageal LP which was refractory to classical 
treatment options (topical clobetasol propi-
onate and pimecrolimus, intramuscular tri-
amcinolone acetonide); because of systemic 
side effects the patient did not tolerate sys-
temic acitretin dosed up to 25 mg daily. 
 Methods: Oral alitretinoin was used at a dose 
of 30 mg daily.  Results: Both oral and skin 
changes as well as dysphagia completely re-
solved within 4 weeks without any severe 
side effects and the drug was used for 6 
months. No papules, intraoral striae or dys-
phagia recurred during the 6 months of 
treatment. After 4 months the patient re-
lapsed with mucosal patches so that a sec-
ond cycle was initiated for 6 months where 
oral LP lesions resolved after 4 weeks also 
(with sporadic mild headache).  Conclusion: 
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phagia. Upon gastroscopy, discrete whitish 
patches were found on the whole esopha-
gus ( fig. 3 a), but the larynx, stomach and 
duodenum were uninvolved. Acitretin was 
then started with 10 mg daily over 2 weeks 
and subsequently increased up to 25 mg 
daily and combined with topical oral clo-
betasol 0.05% gel. The oral lesions de-
creased in size and dysphagia resolved but 
the patient developed fatigue and weight 
loss, so acitretin was reduced to 10 mg dai-
ly for 4 weeks and subsequently stopped 
due to persistence of these side effects. Oral 
and skin changes relapsed after 8 weeks 
with additional involvement of the foot 
nails, hair loss and oral erosions. On the pa-
tient’s wish, the therapy was continued 
only topically with corticosteroids and 
pimecrolimus and led to a stable state. Six 
months later, the patient developed new le-
sions on the right thigh, oral mucosa, dys-
phagia and nail dystrophy on digits IV and 
V on the left hand and on digit I of the right 
foot. Gastroscopy again showed whitish 
lacy patches in the whole esophagus.
 Challenge 
 Cutaneous, oral and esophageal lichen 
planus (LP) was refractory to topical clo-
betasol propionate and pimecrolimus, in-
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tramuscular triamcinolone acetonide and 
systemic acitretin dosed up to 25 mg daily 
which had to be discontinued because of 
systemic side effects. There are several re-
ports on effective treatment of LP unre-
sponsive to classical therapies resolving 
under alitretinoin in cutaneous and muco-
sal but not in esophageal lesions  [1–3] ( ta-
ble 1 ).
 Results 
 The retinoid alitretinoin was started at 
a dose of 30 mg daily. Within 4 weeks both 
oral and skin changes as well as dysphagia 
completely resolved ( fig. 1 b); nail changes 
resolved within 6 months. The patient did 
not report any side effects and used the 
drug for a total of 6 months. No papules, 
intraoral striae or dysphagia recurred over 
the time of treatment. Gastroscopy after 
treatment showed no whitish mucosal 
changes anymore, however two small red-
dish plaques in the proximal esophagus re-
mained ( fig.  3 b), and microscopic persis-
tence of scattered cytotoxic T cell infiltrates 
was detected ( fig. 4 ). After 4 months with-
out treatment, the patient developed two 
new intraoral erosions, but no skin lesions. 
She was treated with low-dose alitretinoin 
10 mg daily and temporarily with 0.1% tri-
amcinolone paste for 2 weeks, but due to 
her oral complaints alitretinoin was raised 
to 30 mg daily again. Within 4 weeks the 
intraoral erosions resolved completely. Af-
ter this second cycle of alitretinoin 30 mg 
daily over 6 months the patient remained 
free of any lesions but complained about 
sporadic mild headache.
 Discussion 
 Lichen ruber planus (Greek  leichen , 
‘tree moss’; Latin  planus , ‘flat’) is a chronic 
inflammatory disease affecting the skin, 
mucous membranes, nails and hair. The 
prevalence of LP is about 0.5–1% of the 
population and LP is characterized by po-
lygonal, flat, pruritic, purple papules to 
Table 1.  Overview of all reported LP patients treated with alitretinoin, including our case
Study Gen-
der
Age Localization Complaints Duration
of LP
Previous 
treatment
Additional 
therapy
Dose Time to 
complete 
response
Treat-
ment
duration
Side effects
Brehmer
et al.,
2011 [1]
f 78 cutaneous erythematous, 
partly confluent, 
scratched papules 
to plaques, mainly 
affecting extremi-
ties, severe pruritus
15 years phototherapy, 
topical calcineu-
rin inhibitors, 
topical cortico-
steroids
topical calcineu-
rin inhibitors, 
topical cortico-
steroids
30 mg/day for 
4 weeks, then 
30 mg/every 
2nd day for
4 weeks
8 weeks 8 weeks –
f 77 muco-
cutaneous
mucosal inflamma-
tion with whitish 
gingival striae, gum 
bleeding, burning
2 years topical calcineu-
rin inhibitors 
and topical 
corticosteroids
topical calcineu-
rin inhibitors and 
topical corticoste-
roids
10 mg/day 4 weeks 4 weeks hypertri-
glyceridemia 
(478 mg/dl)
f 58 cutaneous 
and muco-
cutaneous
itchy papules on
the back and
burning in mouth
– topical calcineu-
rin inhibitors 
and topical 
corticosteroids
topical calcineu-
rin inhibitors and 
topical corticoste-
roids
10 mg/day 4 weeks 4 weeks headache 
and dizzi-
ness
Molin 
and 
Ruzicka,
2010 [2]
m 54 cutaneous itching papules on 
trunk, back, legs, 
forearms, hyperker-
atosis and fissures 
plantar
20 years 
sporadically
topical cortico-
steroids
initially with 
silver nitrate for 
fissures, topical 
betamethasone 
extraplantar, 
combination of 
steroids and 
salicylic acid 
plantar
30 mg/day 16 weeks 
on trunk, 
6 months 
plantar
– –
f 48 cutaneous pruritic papules 
palmoplantar and 
on wrists
7 months – cream PUVA 
3 – 4 times per 
week, initially 
with topical 
mometasone and 
salicylic acid
30 mg/day 5 months – –
Pinter
et al.,
2011 [3]
m 43 cutaneous 
and nails
20 nail dystrophy, 
itching papules on 
both shins
1 year topical and 
systemic antimy-
cotic treatments
– 30 mg/day 6 weeks 
skin, 
24 weeks 
nails
24 weeks –
Present 
report
f 54 cutaneous, 
mucocutane-
ous, esopha-
geal and nails
pruritic papules on 
right medial femo-
ral, intraoral whitish 
striae, dysphagia
3 months topical cortico-
steroids, acitre-
tin, pimecroli-
mus
topical cortico-
steroids
30 mg/day 4 weeks 
skin, 
4 weeks 
nails
2 cycles of 
6 months 
each, totally 
12 months
mild 
headache 
sporadically
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a b
a b
ba
 Fig. 1. Oral mucosa before ( a ) and after ( b ) 
treatment. 
 Fig. 2. Buccal histology, HE staining ( a ) 
and CD8 staining ( b ). 
 Fig. 3. Endoscopy of the esophagus before 
( a ) and after ( b ) treatment. 
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plaques commonly afflicting the wrists, an-
kles or the mucous membranes like the oral 
cavity, vulvovaginal or penile area  [3–5] . 
Nail changes and scarring alopecia can also 
appear. Overlaid, reticulated, white streaks 
called ‘Wickham striae’ can be seen on the 
skin, and mucosal changes enhanced by 
applying water or oil or using dermatosco-
py can be observed.
 Different subtypes have been defined
by configuration or morphology  [5, 6] .
Hypertrophic LP (also called lichen pla-
nus verrucosus) shows hyperkeratotic,
flat-topped, reddish-brown, very pruritic 
plaques which typically affect the anterior 
distal lower extremities with a chronic 
course and normally resolve with scarring, 
associated with hypo- or hyperpigmenta-
tion  [6] . Bullous LP (also called lichen ve-
siculobullosus) presents with vesicles or 
bullae within existing lesions of LP. This di-
agnosis requires prior exclusion of immu-
nobullous disorders. Actinic LP appears as 
atrophic, hyperpigmented, annular, melas-
ma-like, dyschromic or violaceous plaques 
with rolled edge in sun-exposed areas, 
seems to be UV-induced and tends to ap-
pear in patients with pigmented skin  [7–
11] . Linear LP can follow a ‘blaschkoid’ dis-
tribution in adults but is also described in a 
case report of a child  [12–15] . Zosteriform 
LP follows dermatomal lines and is thought 
to be an isotopic response to herpes zoster 
or at least showing antigens against varicel-
la zoster virus in lesional skin  [16–18] . Li-
chen planus pigmentosus-inversus is sug-
gested to be a rare variant of LP limited to 
intertriginous regions and seems to have a 
short inflammatory phase with fast trans-
formation into a long noninflammatory
regressive phase with brown, nonpruritic, 
small inflammatory macules; scaling is lim-
ited  [19–25] . Only one case of coexistence 
of classic LP and lichen planus pigmento-
sus-inversus has been described  [26] . An-
nular atrophic LP is a rare variant of LP
and characterized by annular, violaceous 
plaques with central atrophy. Up to date 10 
cases have been described  [27–35] . Erosive 
LP is a painful variant of LP with eroded or 
ulcerated lesions mainly in mucocutaneous 
sites which is often difficult to treat and may 
lead to scarring  [36–38] . Lichen planus 
pemphigoides refers to a cross-over syn-
drome of LP and bullous pemphigoid  [5] 
and associations with drug intake have been 
described (PUVA  [39] , UVB, paracetamol 
or ibuprofen  [40] , simvastatin  [41] and 
ramipril  [42, 43] ). Several reports show an-
tibodies against 180, 130 and 200 kDa epi-
dermal antigens  [40, 44–51] . Some reports 
also describe an overlap between LP and lu-
pus erythematosus  [52–57] .
 LP shows oral involvement in 30–70% 
 [58, 59] . Oral LP is located commonly in 
the posterior buccal mucosa (about 90%), 
in 30% of cases on the tongue and the
alveolar mucosa. Oral LP presents with
asymptomatic or tender, white, reticulated 
patches to plaques (reticulated oral LP) or 
as painful erosions and ulcers (erosive oral 
LP)  [5, 60] . Bullous LP can involve the mu-
cosal lower lip  [61] . In analogy to adults, 
oral LP in pediatric patients also manifests 
as erosive LP in the buccal mucosa  [62] .
 Genital LP commonly affects the vulva, 
the vagina as well as the glans penis and 
presents as erosive LP  [63, 64] . Without 
treatment it can lead to scarring and disfig-
urement. Lichen sclerosus is the most im-
portant differential diagnosis. Vulvovagi-
nal gingival syndrome is an uncommon 
and severe variant of LP and characterized 
by erosions or desquamation of vulval, vag-
inal and oral mucosa with a predilection for 
scarring and stricture formation, and 80% 
of patients bear the allele DQB1 * 0201 (vs. 
41.8% in the control group)  [65] .
 Esophageal LP was first described in 
1982  [66] and presents with dysphagia, 
odynophagia, heartburn or regurgitation; 
its prevalence ranges from 1 to 50%  [67–
70] , and nearly all patients are women 
(only few male cases  [67, 71] ) older than 40 
years. Esophageal LP is strongly associated 
with oral LP, but genital or skin involve-
ment has been described as well. Esopha-
geal involvement is characterized by le-
sions in the form of peeling of the friable 
mucosa, hyperemic lesions, white plaques, 
ulcers, erosions and stricture formation 
 [67, 72] and typically affects the upper and 
mid esophagus, sparing the gastroesopha-
geal junction, in contrary to reflux esopha-
gitis  [73] .
 In an endoscopic study of 24 patients, 
high-magnification chromoendoscopy was 
used and biopsy samples were taken from 
all levels of the esophagus. In 75% of esoph-
ageal LP patients the diagnosis was made by 
histology of the proximal esophagus, in 
25% of normal-appearing mucosa, in 50% 
of normal-appearing mucosa and focal 
 abnormalities, and in 17% on focal abnor-
malities alone. Endoscopic abnormalities 
ranged from subtle papular lesions, super-
ficial layers of esophageal mucosa peeling 
off, hyperemic lesions, submucosal plaques/
papules, whitish papules, segments of cylin-
drical epithelium above the squamocolum-
nar junction to erosive changes in both 
proximal and distal esophagus  [67, 74] . Re-
flux esophagitis is seen in 15–50% of esoph-
ageal LP patients, but it is controversial 
whether it is a separate condition or sec-
ondary to esophageal LP. A decreased resis-
tance of the esophageal mucosa in esopha-
geal LP has been suggested  [67, 75] .
 Histology resembles that of oral LP and 
shows a band-like or lichenoid lymphocyt-
ic infiltrate involving the superficial lamina 
propria and basal epithelium. In the infil-
trate mature T cells are predominantly 
present and are associated with degenera-
tion of basal keratinocytes, often including 
characteristic Civatte bodies (necrotic ke-
ratinocytes with anucleate remnants). Oth-
er histological findings include dilated in-
tercellular spaces, hyper- or parakerato-
sis, hyperplasia and glycogenic acanthosis 
 [67] . However lymphocytic infiltration is 
not pathognomonic for esophageal LP, and 
other conditions such as infections, reflux 
disease or medications (gold, thiazides, an-
timalarials) can induce LP-like lesions. 
Esophageal LP typically involves the upper 
or mid esophagus which alone would be 
unusual for gastroesophageal reflux disease 
 [76] . Esophageal LP has a chronic course 
and can lead to complications such as dys-
phagia, strictures (40% in the proximal 
esophagus  [68] ) and stenosis which may 
250
200
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Oral LP Esophagus
before
alitretinoin
Esophagus
after
alitretinoin
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*
*
 Fig. 4. CD8+ T cell infiltrates in biopsies
of oral and esophageal lichenoid patches 
before and after 6 months of alitretinoin
(3 high-power fields counted by two inde-
pendent observers).  * Significant, p < 0.001. 
n.s. = Not significant. 
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require dilatation. Different systemic ther-
apies are described. Systemic corticoste-
roids are supposed to be most effective as 
well as retinoids, cyclosporine, azathio-
prine, tacrolimus, rituximab and griseoful-
vin or intralesional corticosteroids  [71, 72, 
76–86] .
 In esophageal LP patients other upper 
gastrointestinal illnesses such as esophagi-
tis, gastritis (up to 91%), bulbitis, duodenal 
ulcer or esophageal sphincter dysfunction 
are described as well and should be investi-
gated  [74, 87] . One case of esophageal LP 
also showed laryngeal and conjunctival in-
volvement, but also a facial and abducens 
nerve paralysis which could be coinciden-
tal; an immunological explanation via mast 
cell activation was suggested  [88, 89] . 
Esophageal LP may also lead to malignant 
transformation and cause squamous cell 
carcinoma ( [76, 90, 91] and unpublished 
data).
 As previous described, due to the differ-
ent findings in endoscopy and histology 
complementing each other or not, esopha-
geal LP is a challenging diagnosis and 
might currently be underestimated.
 Nail changes appear in about 10% of LP 
patients and present as specifically as dor-
sal pterygium (wedge-shaped, raised defor-
mity of the nail bed) and nonspecifically 
with onychorrhexis (longitudinal ridging, 
distal splitting and thinning of the nail 
plate) and trachyonychia. The differential 
diagnosis includes psoriasis, alopecia area-
ta, idiopathic onychorrhexis, nail-patella 
syndrome or onychomycosis  [5] .
 Women are commonly affected much 
more than men by lichen planopilaris, 
which involves the hair follicles and pre-
sents with painful or pruritic, irregularly 
shaped patches of scarring alopecia on the 
frontal, parietal or occipital scalp  [1, 82] . 
28–50% of lichen planopilaris patients 
show LP lesions elsewhere  [92, 93] . Frontal 
fibrosing alopecia and Graham-Little syn-
drome are rare lichen planopilaris variants 
and its differential diagnosis includes dis-
coid lupus erythematosus, cicatricial pem-
phigoid and alopecia areata. Lichen plano-
pilaris may result in cicatrizing alopecia 
 [92, 93] .
 Since 1903 over 90 cases of malignant 
transformation of cutaneous LP into squa-
mous cell carcinoma have been described, 
with a higher incidence in hypertrophic LP 
and the possibility to metastasize  [94, 95] . 
In oral LP a higher risk has been proven 
and the WHO defines oral LP as a ‘pre-
malignant condition’  [96, 97] . Malignant 
transformation in oral LP is about 0.8–10% 
 [59, 89] respectively 1–3%  [98–101] . It has 
been discussed that the chronic inflamma-
tion plays a role in the malignant transfor-
mation of LP by analogy to ulcerative coli-
tis and colorectal carcinoma  [102] . Ma-
lignant transformation to squamous cell 
carcinoma is also described in penile, anal 
and vulvovaginal LP as well as in esopha-
geal LP  [90, 91, 103–108] , as it was ob-
served in another case at our hospital that 
developed an esophageal carcinoma within 
a chronic LP of the esophagus. With the 
chronic course of LP, especially in its hy-
pertrophic variant, and an incidence of 
9–26% in pediatric LP, it is very important 
to keep the risk of malignant transforma-
tion in mind, particularly in those patients 
 [109, 110] . Cyclooxygenase-2 (COX-2) 
plays a role in inflammation as well as in 
cancer development. It could be shown 
that in LP lesions COX-2 is increased and 
microRNA-26b (an inhibitor of COX-2) is 
decreased, together possibly leading to 
COX-2 increase with a stronger activation 
of inflammation and carcinogenesis  [111] .
a b
a b
 Fig. 6. Esophageal immunohistology of IL-17 before ( a ) and after ( b ) treatment. 
 Fig. 5. Esophageal immunohistology of IL-1β before ( a ) and after ( b ) treatment. 
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 The pathogenesis is as yet unclear, but 
associations with hepatitis C, diabetes, ge-
netic background, dental materials, drugs, 
infections, autoimmunity, immunodefi-
ciency, stress and malignant neoplasms 
have been described  [60] .
 The histopathology of LP is characteris-
tic with hyperkeratosis, focal hypergranu-
losis, irregular sawtooth-like acanthosis, 
vacuolar degeneration of the dermo-epi-
dermal junction zone and band-like lym-
phocytic infiltrates. Sometimes Civatte 
bodies, which are hyaline, amorphous 
apoptotic keratinocytes, and Caspary-Jo-
seph spaces, which is a confluence of vacu-
olar degeneration, are found.
 Recently different immunological 
modifications have been reported, includ-
ing modulation of Toll-like receptors 2 
 [112] and 4 that bind bacterial lipopeptides 
and lipopolysaccharide, suggesting chron-
ic host-pathogen interactions in oral LP 
whereby the pathogen may be a microor-
ganism present on the skin and/or in saliva 
 [113] . The majority of epithelial lympho-
cytes are CD8+ whereas in dermal tissue 
more CD4+ lymphocytes are present  [114, 
115] .
 Also increased expression of micro-
RNA-146a and microRNA-155 in oral LP, 
which are also found in other inflamma-
tory and autoimmune diseases like lupus 
erythematosus, as well as a polymorphism 
of DNMT3B (DNA methyltransferase 3b) 
have been described  [116–119] . These mi-
croRNAs appear to favor Th1 responses by 
IFN-γ signaling and may be involved in re-
duced T-reg activation  [120, 121] .
 Increased levels of TNF-α, RANTES-
dependent mast cell degranulation and 
matrix metalloproteinase facilitate T cell 
migration into connective tissue  [122–
124] . Additionally, increased levels of IL-
1α, IL-6 and IL-8 in oral lesions may indi-
cate a NF-κB-dependent immune activa-
tion pathway  [125] .
 Interestingly, elevated serum levels of 
IL-17 have also been found in patients suf-
fering from oral LP and hepatitis C, and
IL-17 also causes a matrix metalloprotein-
ase response  [126] . We performed esopha-
geal immunohistology with IL-1β ( fig.  5 ) 
and IL-17 ( fig. 6 ) stainings which were pos-
itive compared with controls but did not 
show a significant difference between be-
fore and after treatment.
 A large choice of treatment options for 
LP is available, including topical cortico-
steroids, topical calcineurin inhibitors, 
phototherapy, systemic steroids, systemic 
cyclosporine, thalidomide  [127] and myco-
phenolate mofetil  [128] . TNF-α inhibitors 
like etanercept  [129, 130] and adalimumab 
 [4, 131] can ameliorate but paradoxically 
also elicit LP. Meta-analyses show very 
weak evidence of effectiveness of any treat-
ment of oral and erosive LP  [37, 132, 133] .
 The RXR/RAR ligand alitretinoin re-
sulted in suppression of multifocal lichen 
ruber planus, including the potentially 
dangerous esophageal involvement that 
can predispose to spinocellular carcinoma 
( [134] and own unpublished observation).
 In our case the patient was unrespon-
sive to or suffered from side effects from 
previous therapies including topical cor-
ticosteroids, topical pimecrolimus and 
acitretin. We therefore chose a regimen of 
30 mg alitretinoin daily over a period of 24 
weeks, as it is used for chronic hand eczema 
with clearance up to 48%  [135] . In the hope 
of stabilizing remission we extended the 
treatment with alitretinoin 30 mg daily.
 Taken together, this case reports the 
successful use of alitretinoin for esophageal 
LP with dysphagia. All sites of lichen ruber 
planus improved under therapy with ali-
tretinoin ( table 1 ). We propose that alitre-
tinoin may be effective in suppressing dis-
ease activity in LP, but may not definitively 
inactivate the immunologic process driv-
ing LP within a 6-month course of therapy. 
In our case, at the end of 24 weeks of treat-
ment with alitretinoin, scattered mucosal 
CD8+ T cell infiltrates in the esophagus 
were still detectable, suggesting that thera-
py beyond 6 months may be of value (as in 
our patient a second course of treatment 
over 6 months was necessary).
 Alitretinoin could be a future addition-
al treatment option for LP, including LP 
with esophageal involvement, in case of 
nonresponse to previous treatments. A 
larger monocentric, prospective, open-la-
bel study (NCT01538732) is currently be-
ing performed at our department to further 
investigate this question.
 Author Contributions 
 A. Navarini and A.G.A. Kolios had full 
access to all of the data in the study and take 
responsibility for the integrity of the data 
and the accuracy of the data analysis. Study 
concept and design: A.G.A. Kolios, A. Na-
varini. Acquisition of data: A.G.A. Kolios, 
E. Marques Maggio, C. Gubler. Analysis 
and interpretation of data: A. Navarini, 
A.G.A. Kolios, A. Cozzio, R. Dummer, L.E. 
French. Drafting of the manuscript: A. Na-
varini, A.G.A. Kolios, R. Dummer, L.E. 
French. Critical revision of the manuscript 
for important intellectual content: A. Na-
varini, E. Marques Maggio, C. Gubler,
A. Cozzio, R. Dummer, L.E. French. Ob-
tained funding: A. Navarini. Administra-
tive, technical or material support: A. Na-
varini, E. Marques Maggio, A.G.A. Kolios. 
Study supervision: A. Navarini, R. Dum-
mer, L.E. French.
 Acknowledgement 
 This study was supported by the De-
partment of Dermatology, University Hos-
pital of Zurich.
 Disclosure Statement 
 None of the authors have any financial 
relationships relevant to this paper.
 
 References 
 1 Brehmer F, Haenssle HA, Schon MP, Emmert 
S: Response of recalcitrant lichen planus to 
alitretinoin in 3 patients. J Am Acad Dermatol 
2011; 65:e58–e60. 
 2 Molin S, Ruzicka T: Oral alitretinoin in lichen 
planus: two case reports. Acta Derm Venereol 
2010; 90: 523–524. 
 3 Pinter A, Patzold S, Kaufmann R: Lichen pla-
nus of nails – successful treatment with Ali-
tretinoin. J Dtsch Dermatol Ges 2011; 9: 1033–
1034. 
 4 Hollo P, Szakonyi J, Kiss D, Jokai H, Horvath 
A, Karpati S: Successful treatment of lichen 
planus with adalimumab. Acta Derm Vene-
reol 2012; 92: 385–386. 
 5 Lehman JS, Tollefson MM, Gibson LE: Lichen 
planus. Int J Dermatol 2009; 48: 682–694. 
 6 Wolf R, Ruzicka T, Rupec RA: Pleomorphis-
mus des Lichen ruber – klinische Variations-
breite, Pathogenese und Therapie. Akt Der-
matol 2010; 36: 180–185. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
14
4.
20
0.
17
.4
0 
- 1
1/
4/
20
13
 1
0:
41
:1
9 
AM
 Kolios  /Marques Maggio  /Gubler  /Cozzio  /
Dummer  /French  /Navarini  
 
Dermatology 2013;226:302–310
DOI: 10.1159/000349980
308
 7 Peretz E, Grunwald MH, Halevy S: Annular 
plaque on the face. Actinic lichen planus 
(ALP). Arch Dermatol 1999; 135: 1543, 1546. 
 8 Kim GH, Mikkilineni R: Lichen planus acti-
nicus. Dermatol Online J 2007; 13: 13. 
 9 Meads SB, Kunishige J, Ramos-Caro FA, Has-
sanein AM: Lichen planus actinicus. Cutis 
2003; 72: 377–381. 
 10 Zanca A: Lichen planus actinicus. Int J Der-
matol 1978; 17: 506–508. 
 11 Baker H, Almeyda J: Lichen planus actinicus. 
Br J Dermatol 1970; 82: 426–427. 
 12 Happle R: Superimposed segmental manifes-
tation of polygenic skin disorders. J Am Acad 
Dermatol 2007; 57: 690–699. 
 13 Ber Rahman S, Ul Bari A, Mumtaz N: Unilat-
eral Blaschkoid lichen planus involving the 
entire half of the body, a unique presentation. 
Dermatol Online J 2007; 13: 36. 
 14 Sharma R, Maheshwari V, Chandra M: Uni-
lateral multiple linear lichen planus along the 
lines of Blaschko: a report of two cases. Indian 
J Dermatol Venereol Leprol 1999; 65: 225–
226. 
 15 Kabbash C, Laude TA, Weinberg JM, Silver-
berg NB: Lichen planus in the lines of Blasch-
ko. Pediatr Dermatol 2002; 19: 541–545. 
 16 Turel A, Ozturkcan S, Sahin MT, Turkdogan 
P: Wolf’s isotopic response: a case of zosteri-
form lichen planus. J Dermatol 2002; 29: 339–
342. 
 17 Mohrenschlager M, Engst R, Hein R, Ring J: 
Primary manifestation of a zosteriform lichen 
planus: isotopic response following herpes 
zoster sine herpete? Br J Dermatol 2008; 158: 
 1145–1146. 
 18 Mizukawa Y, Horie C, Yamazaki Y, Shiohara 
T: Detection of varicella-zoster virus antigens 
in lesional skin of zosteriform lichen planus 
but not in that of linear lichen planus. Derma-
tology 2012; 225: 22–26. 
 19 Dostrovsky A, Sagher F: Lichen planus in sub-
tropical countries; study of an annular type 
with inverse localization (uncovered surfaces 
of the skin). Arch Derm Syphilol 1949; 59: 
 308–328. 
 20 Pock L, Jelinkova L, Drlik L, et al: Lichen pla-
nus pigmentosus-inversus. J Eur Acad Der-
matol Venereol 2001; 15: 452–454. 
 21 Kashima A, Tajiri A, Yamashita A, Asada Y, 
Setoyama M: Two Japanese cases of lichen 
planus pigmentosus-inversus. Int J Dermatol 
2007; 46: 740–742. 
 22 Bennassar A, Mas A, Julia M, Iranzo P, Fer-
rando J: Annular plaques in the skin folds:
4 cases of lichen planus pigmentosus-inversus 
(in Spanish). Actas Dermosifiliogr 2009; 100: 
 602–605. 
 23 Jung YJ, Lee YH, Lee SY, Lee WS: A case of 
lichen planus pigmentosus-inversus in a Ko-
rean patient. Ann Dermatol 2011; 23: 61–63. 
 24 Ohshima N, Shirai A, Saito I, Asahina A: Li-
chen planus pigmentosus-inversus occurring 
extensively in multiple intertriginous areas. J 
Dermatol 2012; 39: 412–414. 
 25 Gaertner E, Elstein W: Lichen planus pigmen-
tosus-inversus: case report and review of an 
unusual entity. Dermatol Online J 2012; 18: 11. 
 26 Kim BS, Aum JA, Kim HS, et al: Coexistence of 
classic lichen planus and lichen planus pigmen-
tosus-inversus: resistant to both tacrolimus and 
clobetasol propionate ointments. J Eur Acad 
Dermatol Venereol 2008; 22: 106–107. 
 27 Requena L, Olivares M, Pique E, Farina MC, 
Martin L: Annular atrophic lichen planus. 
Dermatology 1994; 189: 95–98. 
 28 Lipsker D, Piette JC, Laporte JL, Maunoury L, 
Frances C: Annular atrophic lichen planus 
and Sneddon’s syndrome. Dermatology 1997; 
 195: 402–403. 
 29 Mseddi M, Bouassida S, Marrakchi S, Khe-
makhem M, Turki H, Zahaf A: Annular atro-
phic lichen planus. Dermatology 2003; 207: 
 208–209. 
 30 Morales-Callaghan A Jr, Martinez G, Ara-
goneses H, Miranda-Romero A: Annular 
atrophic lichen planus. J Am Acad Dermatol 
2005; 52: 906–908. 
 31 Ponce-Olivera RM, Tirado-Sanchez A, Mon-
tes-de-Oca-Sanchez G, Leon-Dorantes G, 
Mercadillo-Perez P: Annular atrophic lichen 
planus. Int J Dermatol 2007; 46: 490–491. 
 32 Kim JS, Kang MS, Sagong C, Yu HJ: Annular 
atrophic lichen planus associated with hyper-
trophic lichen planus. Clin Exp Dermatol 
2008; 33: 195–197. 
 33 Serrao VV, Organ V, Pereira L, Vale E, Cor-
reia S: Annular lichen planus in association 
with Crohn disease. Dermatol Online J 2008; 
 14: 5. 
 34 Li B, Li JH, Xiao T, He CD, Gao XH, Chen 
HD: Annular atrophic lichen planus. Eur J 
Dermatol 2010; 20: 842–843. 
 35 Sugashima Y, Yamamoto T: Letter: Annular 
atrophic lichen planus of the lip. Dermatol 
Online J 2012; 18: 14. 
 36 Simpson RC, Littlewood SM, Cooper SM, et 
al: Real-life experience of managing vulval 
erosive lichen planus: a case-based review and 
U.K. multicentre case note audit. Br J Derma-
tol 2012; 167: 85–91. 
 37 Cheng S, Kirtschig G, Cooper S, Thornhill
M, Leonardi-Bee J, Murphy R: Interventions 
for erosive lichen planus affecting mucosal 
sites. Cochrane Database Syst Rev 2012; 2:
CD008092. 
 38 Goucha S, Khaled A, Bennani Z, et al: Erosive 
lichen planus of the soles: effective response 
to prednisone. Dermatol Ther (Heidelb) 
2011; 1: 20–24. 
 39 Kuramoto N, Kishimoto S, Shibagaki R, Ya-
suno H: PUVA-induced lichen planus pem-
phigoides. Br J Dermatol 2000; 142: 509–512. 
 40 Maoz KB, Brenner S: Lichen planus pem-
phigoides triggered by narrowband UVB, 
paracetamol, and ibuprofen, with autoanti-
bodies to 130 kDa antigen. Skinmed 2008; 7: 
 33–36. 
 41 Stoebner PE, Michot C, Ligeron C, Durand L, 
Meynadier J, Meunier L: Simvastatin-induced 
lichen planus pemphigoides (in French). Ann 
Dermatol Venereol 2003; 130(2 Pt 1):187–190. 
 42 Zhu YI, Fitzpatrick JE, Kornfeld BW: Li-
chen planus pemphigoides associated with 
ramipril. Int J Dermatol 2006; 45: 1453–1455. 
 43 Ogg GS, Bhogal BS, Hashimoto T, Coleman 
R, Barker JN: Ramipril-associated lichen pla-
nus pemphigoides. Br J Dermatol 1997; 136: 
 412–414. 
 44 Yoon KH, Kim SC, Kang DS, Lee IJ: Lichen 
planus pemphigoides with circulating auto-
antibodies against 200 and 180 kDa epidermal 
antigens. Eur J Dermatol 2000; 10: 212–214. 
 45 Hsu S, Ghohestani RF, Uitto J: Lichen planus 
pemphigoides with IgG autoantibodies to the 
180 kd bullous pemphigoid antigen (type 
XVII collagen). J Am Acad Dermatol 2000; 
 42(1 Pt 1):136–141. 
 46 Mignogna MD, Fortuna G, Leuci S, Stasio L, 
Mezza E, Ruoppo E: Lichen planus pemphi-
goides, a possible example of epitope spread-
ing. Oral Surg Oral Med Oral Pathol Oral Ra-
diol Endod 2010; 109: 837–843. 
 47 Barnadas MA, Roe E, Dalmau J, Alomar A, 
Martinez L, Gelpi C: Lichen planus pemphi-
goides: detection of anti-BP 180 antibodies by 
ELISA and immunoblotting tests. J Eur Acad 
Dermatol Venereol 2010; 24: 1360–1361. 
 48 Cohen DM, Ben-Amitai D, Feinmesser M, 
Zvulunov A: Childhood lichen planus pem-
phigoides: a case report and review of the lit-
erature. Pediatr Dermatol 2009; 26: 569–574. 
 49 Harting MS, Hsu S: Lichen planus pemphi-
goides: a case report and review of the litera-
ture. Dermatol Online J 2006; 12: 10. 
 50 Skaria M, Salomon D, Jaunin F, Friedli A, 
Saurat JH, Borradori L: IgG autoantibodies 
from a lichen planus pemphigoides patient 
recognize the NC16A domain of the bullous 
pemphigoid antigen 180. Dermatology 1999; 
 199: 253–255. 
 51 Zillikens D, Caux F, Mascaro JM, et al: Auto-
antibodies in lichen planus pemphigoides re-
act with a novel epitope within the C-terminal 
NC16A domain of BP180. J Invest Dermatol 
1999; 113: 117–121. 
 52 Romero RW, Nesbitt LT Jr, Reed RJ: Unusual 
variant of lupus erythematosus or lichen pla-
nus. Clinical, histopathologic, and immuno-
fluorescent studies. Arch Dermatol 1977; 113: 
 741–748. 
 53 Copeman PW, Schroeter AL, Kierland RR: 
An unusual variant of lupus erythematosus or 
lichen planus. Br J Dermatol 1970; 83: 269–
272. 
 54 Nagao K, Chen KR: A case of lupus erythema-
tosus/lichen planus overlap syndrome. J Der-
matol 2006; 33: 187–190. 
 55 Muller FB, Groth W, Mahrle G: Multiple
autoimmune syndrome. Reynolds-syndrome 
(acral scleroderma, primary biliary cirrhosis, 
Sjögren syndrome) associated with the lupus 
erythematosus/lichen planus overlap syn-
drome (in German). Hautarzt 2004; 55: 465–
470. 
 56 Inaloz HS, Chowdhury MM, Motley RJ: Lu-
pus erythematosus/lichen planus overlap syn-
drome with scarring alopecia. J Eur Acad Der-
matol Venereol 2001; 15: 171–174. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
14
4.
20
0.
17
.4
0 
- 1
1/
4/
20
13
 1
0:
41
:1
9 
AM
 Oral, Esophageal and Cutaneous Lichen 
Ruber Planus Controlled with Alitretinoin 
Dermatology 2013;226:302–310
DOI: 10.1159/000349980
309
 57 Mahler V, Hornstein OP, Meyer S, Albrecht 
HP, Kiesewetter F: Lupus erythematosus/li-
chen ruber planus overlap syndrome. 5 cases 
in a patient sample of the Erlangen University 
Dermatology Clinic (1894–1995) (in Ger-
man). Hautarzt 1998; 49: 295–302. 
 58 Arisawa EA, Almeida JD, Carvalho YR, Ca-
bral LA: Clinicopathological analysis of oral 
mucous autoimmune disease: a 27-year study. 
Med Oral Patol Oral Cir Bucal 2008; 13:E94–
E97. 
 59 Altman J, Perry HO: The variations and 
course of lichen planus. Arch Dermatol 1961; 
 84: 179–191. 
 60 Scully C, Beyli M, Ferreiro MC, et al: Update 
on oral lichen planus: etiopathogenesis and 
management. Crit Rev Oral Biol Med 1998; 9: 
 86–122. 
 61 van Tuyll van Serooskerken AM, van Marion 
AM, de Zwart-Storm E, Frank J, Poblete-
Gutierrez P: Lichen planus with bullous man-
ifestation on the lip. Int J Dermatol 2007; 
 46(suppl 3):25–26. 
 62 Chatterjee K, Bhattacharya S, Mukherjee CG, 
Mazumdar A: A retrospective study of oral li-
chen planus in paediatric population. J Oral 
Maxillofac Pathol 2012; 16: 363–367. 
 63 Goldstein AT, Metz A: Vulvar lichen planus. 
Clin Obstet Gynecol 2005; 48: 818–823. 
 64 O’Connell TX, Nathan LS, Satmary WA, 
Goldstein AT: Non-neoplastic epithelial dis-
orders of the vulva. Am Fam Physician 2008; 
 77: 321–326. 
 65 Setterfield JF, Neill S, Shirlaw PJ, et al: The 
vulvovaginal gingival syndrome: a severe sub-
group of lichen planus with characteristic 
clinical features and a novel association with 
the class II HLA DQB1 * 0201 allele. J Am 
Acad Dermatol 2006; 55: 98–113. 
 66 Al-Shihabi BM, Jackson JM: Dysphagia due to 
pharyngeal and oesophageal lichen planus. J 
Laryngol Otol 1982; 96: 567–571. 
 67 Quispel R, van Boxel OS, Schipper ME, et al: 
High prevalence of esophageal involvement 
in lichen planus: a study using magnification 
chromoendoscopy. Endoscopy 2009; 41: 187–
193. 
 68 Katzka DA, Smyrk TC, Bruce AJ, Romero Y, 
Alexander JA, Murray JA: Variations in pre-
sentations of esophageal involvement in li-
chen planus. Clin Gastroenterol Hepatol 
2010; 8: 777–782. 
 69 Fox LP, Lightdale CJ, Grossman ME: Lichen 
planus of the esophagus: what dermatologists 
need to know. J Am Acad Dermatol 2011; 65: 
 175–183. 
 70 Yoon RY, Sullivan SN: Esophageal lichen pla-
nus. Gastrointest Endosc 1990; 36: 617–619. 
 71 Chryssostalis A, Gaudric M, Terris B, Coriat 
R, Prat F, Chaussade S: Esophageal lichen pla-
nus: a series of eight cases including a patient 
with esophageal verrucous carcinoma. A case 
series. Endoscopy 2008; 40: 764–768. 
 72 Abraham SC, Ravich WJ, Anhalt GJ, Yardley 
JH, Wu TT: Esophageal lichen planus: case re-
port and review of the literature. Am J Surg 
Pathol 2000; 24: 1678–1682. 
 73 Williams TR, Haider-Shah H: Diffuse esoph-
ageal stricture secondary to esophageal lichen 
planus. Abdom Imaging 2005; 30: 355–357. 
 74 Sanli H, Cetinkaya H, Tursen U, Kaya M, 
Kuzu I, Gurler A: Upper gastrointestinal find-
ings in oral lichen planus. Turk J Gastroen-
terol 2002; 13: 31–34. 
 75 Ronkainen J, Aro P, Storskrubb T, et al: High 
prevalence of gastroesophageal reflux symp-
toms and esophagitis with or without symp-
toms in the general adult Swedish population: 
a Kalixanda study report. Scand J Gastroen-
terol 2005; 40: 275–285. 
 76 Chandan VS, Murray JA, Abraham SC: 
Esophageal lichen planus. Arch Pathol Lab 
Med 2008; 132: 1026–1029. 
 77 Valdes F, Caparrini A, Calzada JM: Lichen 
planus with esophageal involvement (in 
Spanish. Actas Dermosifiliogr 2007; 98: 361–
364. 
 78 Harewood GC, Murray JA, Cameron AJ: 
Esophageal lichen planus: the Mayo Clinic ex-
perience. Dis Esophagus 1999; 12: 309–311. 
 79 Van Maercke P, Gunther M, Groth W, Gheor-
ghiu T, Habermann U: Lichen ruber mucosae 
with esophageal involvement. Endoscopy 
1988; 20: 158–160. 
 80 Schiavino D, Murzilli F, Forti G, Chiarelli C, 
Altomonte L, Magaro M: Mucocutaneous li-
chen planus with esophageal involvement. A 
clinical case (in Italian). Minerva Med 1992; 
 83: 73–76. 
 81 Bobadilla J, van der Hulst RW, ten Kate FJ, 
Tytgat GN: Esophageal lichen planus. Gastro-
intest Endosc 1999; 50: 268–271. 
 82 Madhusudhan KS, Sharma R: Esophageal li-
chen planus: a case report and review of lit-
erature. Indian J Dermatol 2008; 53: 26–27. 
 83 Keate RF, Williams JW, Connolly SM: Lichen 
planus esophagitis: report of three patients 
treated with oral tacrolimus or intraesopha-
geal corticosteroid injections or both. Dis 
Esophagus 2003; 16: 47–53. 
 84 Parmentier L, Bron BA, Prins C, Samson J, 
Masouye I, Borradori L: Mucocutaneous li-
chen planus with esophageal involvement: 
successful treatment with an anti-CD20 
monoclonal antibody. Arch Dermatol 2008; 
 144: 1427–1430. 
 85 Donnellan F, Swan MP, May GR, Kandel G, 
Marcon NE, Kortan PP: Fluticasone propio-
nate for treatment of esophageal lichen pla-
nus. A case series. Dis Esophagus 2011; 24: 
 211–214. 
 86 Chaklader M, Morris-Larkin C, Gulliver W, 
McGrath J: Cyclosporine in the management 
of esophageal lichen planus. Can J Gastroen-
terol 2009; 23: 686–688. 
 87 Izol B, Karabulut AA, Biyikoglu I, Gonultas 
M, Eksioglu M: Investigation of upper gas-
trointestinal tract involvement and  H. pylori 
presence in lichen planus: a case-controlled 
study with endoscopic and histopathologi-
cal findings. Int J Dermatol 2010; 49: 1121–
1126. 
 88 Tunca A, Calikoglu E, Aktas D, Safak N, Us-
tun H: Oral lichen planus: an unusual cause 
of facial and abducens nerve paralysis asso-
ciated with conjunctival and oesophageal in-
volvement. J Eur Acad Dermatol Venereol 
2004; 18: 630–633. 
 89 Menges M, Hohloch K, Pueschel W, Stall-
mach A: Lichen planus with oesophageal in-
volvement. A case report and review of the 
literature. Digestion 2002; 65: 184–189. 
 90 Schwartz MP, Sigurdsson V, Vreuls W, Lub-
bert PH, Smout AJ: Two siblings with lichen 
planus and squamous cell carcinoma of the 
oesophagus. Eur J Gastroenterol Hepatol 
2006; 18: 1111–1115. 
 91 Aubert A, Hammel P, Perniceni T, et al: Epi-
dermoid carcinoma complicating esopha-
geal lichen planus without cutaneous or oral 
involvement. Gastrointest Endosc 2011; 74: 
 221–223. 
 92 Cevasco NC, Bergfeld WF, Remzi BK, de 
Knott HR: A case-series of 29 patients with 
lichen planopilaris: the Cleveland Clinic 
Foundation experience on evaluation, diag-
nosis, and treatment. J Am Acad Dermatol 
2007; 57: 47–53. 
 93 Mehregan DA, Van Hale HM, Muller SA: Li-
chen planopilaris: clinical and pathologic 
study of forty-five patients. J Am Acad Der-
matol 1992; 27(6 Pt 1):935–942. 
 94 Friedl TK, Flaig MJ, Ruzicka T, Rupec RA: 
Verrucous squamous cell carcinoma com-
plicating hypertrophic lichen planus. Three 
case reports and review of the literature (in 
German). Hautarzt 2011; 62: 40–45. 
 95 Ardabili M, Gambichler T, Rotterdam S, Alt-
meyer P, Hoffmann K, Stucker M: Metastatic 
cutaneous squamous cell carcinoma arising 
from a previous area of chronic hypertrophic 
lichen planus. Dermatol Online J 2003; 9: 10. 
 96 Sigurgeirsson B, Lindelof B: Lichen planus 
and malignancy. An epidemiologic study of 
2071 patients and a review of the literature. 
Arch Dermatol 1991; 127: 1684–1688. 
 97 Pindborg JJ, Wahi PN: Histological Typing 
of Cancer and Precancer of the Oral Mucosa. 
Berlin/Heidelberg, Springer, 1997. 
 98 Silverman S Jr, Gorsky M, Lozada-Nur F,
Giannotti K: A prospective study of findings 
and management in 214 patients with oral 
lichen planus. Oral Surg Oral Med Oral 
Pathol 1991; 72: 665–670. 
 99 Silverman S Jr, Gorsky M, Lozada-Nur F: A 
prospective follow-up study of 570 patients 
with oral lichen planus: persistence, remis-
sion, and malignant association. Oral Surg 
Oral Med Oral Pathol 1985; 60: 30–34. 
 100 Eisen D: The clinical manifestations and 
treatment of oral lichen planus. Dermatol 
Clin 2003; 21: 79–89. 
 101 Lodi G, Scully C, Carrozzo M, Griffiths M, 
Sugerman PB, Thongprasom K: Current 
controversies in oral lichen planus: report of 
an international consensus meeting. Part 2. 
Clinical management and malignant trans-
formation. Oral Surg Oral Med Oral Pathol 
Oral Radiol Endod 2005; 100: 164–178. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
14
4.
20
0.
17
.4
0 
- 1
1/
4/
20
13
 1
0:
41
:1
9 
AM
 Kolios  /Marques Maggio  /Gubler  /Cozzio  /
Dummer  /French  /Navarini  
 
Dermatology 2013;226:302–310
DOI: 10.1159/000349980
310
 102 Mignogna MD, Fedele S, Lo Russo L, Lo 
Muzio L, Bucci E: Immune activation and 
chronic inflammation as the cause of malig-
nancy in oral lichen planus: is there any evi-
dence? Oral Oncol 2004; 40: 120–130. 
 103 Franck JM, Young AW Jr: Squamous cell 
carcinoma in situ arising within lichen pla-
nus of the vulva. Dermatol Surg 1995; 21: 
 890–894. 
 104 Dwyer CM, Kerr RE, Millan DW: Squamous 
carcinoma following lichen planus of the 
vulva. Clin Exp Dermatol 1995; 20: 171–172. 
 105 Leal-Khouri S, Hruza GJ: Squamous cell car-
cinoma developing within lichen planus of 
the penis. Treatment with Mohs micro-
graphic surgery. J Dermatol Surg Oncol 
1994; 20: 272–276. 
 106 Worheide J, Bonsmann G, Kolde G, Hamm 
H: Squamous epithelial carcinoma at the site 
of lichen ruber hypertrophicus of the glans 
penis (in German). Hautarzt 1991; 42: 112–
115. 
 107 Gupta R, Bansal B, Singh S, Yadav I, Gupta 
K, Kudesia M: Lichen planus of uterine cer-
vix – the first report of a novel site of occur-
rence: a case report. Cases J 2009; 2: 9306. 
 108 Fundaro S, Spallanzani A, Ricchi E, et al: 
Squamous-cell carcinoma developing with-
in anal lichen planus: report of a case. Dis 
Colon Rectum 1998; 41: 111–114. 
 109 Sharma R, Maheshwari V: Childhood lichen 
planus: a report of fifty cases. Pediatr Der-
matol 1999; 16: 345–348. 
 110 Handa S, Sahoo B: Childhood lichen planus: 
a study of 87 cases. Int J Dermatol 2002; 41: 
 423–427. 
 111 Danielsson K, Ebrahimi M, Wahlin YB, Ny-
lander K, Boldrup L: Increased levels of 
COX-2 in oral lichen planus supports an au-
toimmune cause of the disease. J Eur Acad 
Dermatol Venereol 2012; 26: 1415–1419. 
 112 Ohno S, Tateishi Y, Tatemoto Y, Morishita 
K, Sasabe E, Yamamoto T: Enhanced expres-
sion of Toll-like receptor 2 in lesional tissues 
and peripheral blood monocytes of patients 
with oral lichen planus. J Dermatol 2011; 38: 
 335–344. 
 113 Janardhanam SB, Prakasam S, Swaminathan 
VT, Kodumudi KN, Zunt SL, Srinivasan M: 
Differential expression of TLR-2 and TLR-4 
in the epithelial cells in oral lichen planus. 
Arch Oral Biol 2012; 57: 495–502. 
 114 Sugerman PB, Savage NW, Walsh LJ, et al: 
The pathogenesis of oral lichen planus. Crit 
Rev Oral Biol Med 2002; 13: 350–365. 
 115 Matthews JB, Scully CM, Potts AJ: Oral li-
chen planus: an immunoperoxidase study 
using monoclonal antibodies to lymphocyte 
subsets. Br J Dermatol 1984; 111: 587–595. 
 116 Fonseca-Silva T, Oliveira MV, Fraga CA, et 
al: DNMT3B (C46359T) polymorphisms 
and immunoexpression of DNMT3b and 
DNMT1 proteins in oral lichen planus. 
Pathobiology 2012; 79: 18–23. 
 117 Arao TC, Guimaraes AL, de Paula AM, 
Gomes CC, Gomez RS: Increased miRNA-
146a and miRNA-155 expressions in oral li-
chen planus. Arch Dermatol Res 2012; 304: 
 371–375. 
 118 Pauley KM, Cha S, Chan EK: MicroRNA in 
autoimmunity and autoimmune diseases. J 
Autoimmun 2009; 32: 189–194. 
 119 Coppede F, Zitarosa MT, Migheli F, et al: 
DNMT3B promoter polymorphisms and 
risk of late onset Alzheimer’s disease. Curr 
Alzheimer Res 2012; 9: 550–554. 
 120 Banerjee A, Schambach F, DeJong CS, Ham-
mond SM, Reiner SL: Micro-RNA-155 in-
hibits IFN-gamma signaling in CD4+ T 
cells. Eur J Immunol 2010; 40: 225–231. 
 121 Tang Y, Luo X, Cui H, et al: MicroRNA-
146A contributes to abnormal activation of 
the type I interferon pathway in human lu-
pus by targeting the key signaling proteins. 
Arthritis Rheum 2009; 60: 1065–1075. 
 122 Erdem MT, Gulec AI, Kiziltunc A, Yildirim 
A, Atasoy M: Increased serum levels of tu-
mor necrosis factor alpha in lichen planus. 
Dermatology 2003; 207: 367–370. 
 123 Sharma R, Sircar K, Singh S, Rastogi V: Role 
of mast cells in pathogenesis of oral lichen 
planus. J Oral Maxillofac Pathol 2011; 15: 
 267–271. 
 124 Zhao ZZ, Savage NW, Sugerman PB, Walsh 
LJ: Mast cell/T cell interactions in oral lichen 
planus. J Oral Pathol Med 2002; 31: 189–195. 
 125 Rhodus NL, Cheng B, Ondrey F: Th1/Th2 
cytokine ratio in tissue transudates from pa-
tients with oral lichen planus. Mediators In-
flamm 2007; 2007: 19854. 
 126 Shaker O, Hassan AS: Possible role of inter-
leukin-17 in the pathogenesis of lichen pla-
nus. Br J Dermatol 2012; 166: 1367–1368. 
 127 Maender JL, Krishnan RS, Angel TA, Hsu S: 
Complete resolution of generalized lichen 
planus after treatment with thalidomide. J 
Drugs Dermatol 2005; 4: 86–88. 
 128 Wee JS, Shirlaw PJ, Challacombe SJ, Setter-
field JF: Efficacy of mycophenolate mofetil 
in severe mucocutaneous lichen planus: a 
retrospective review of 10 patients. Br J Der-
matol 2012; 167: 36–43. 
 129 Yarom N: Etanercept for the management of 
oral lichen planus. Am J Clin Dermatol 2007; 
 8: 121. 
 130 Irla N, Schneiter T, Haneke E, Yawalkar N: 
Nail lichen planus: successful treatment with 
etanercept. Case Rep Dermatol 2010; 2: 173–
176. 
 131 Chao TJ: Adalimumab in the management 
of cutaneous and oral lichen planus. Cutis 
2009; 84: 325–328. 
 132 Lodi G, Carrozzo M, Furness S, Thongpra-
som K: Interventions for treating oral lichen 
planus: a systematic review. Br J Dermatol 
2012; 166: 938–947. 
 133 Keenan AV, Ferraiolo D: Insufficient evi-
dence for effectiveness of any treatment for 
oral lichen planus. Evid Based Dent 2011; 12: 
 85–86. 
 134 Calabrese C, Fabbri A, Benni M, et al: Squa-
mous cell carcinoma arising in esophageal 
lichen planus. Gastrointest Endosc 2003; 57: 
 596–599. 
 135 Ruzicka T, Lynde CW, Jemec GB, et al: Ef-
ficacy and safety of oral alitretinoin (9-cis 
retinoic acid) in patients with severe chronic 
hand eczema refractory to topical corticoste-
roids: results of a randomized, double-blind, 
placebo-controlled, multicentre trial. Br J 
Dermatol 2008; 158: 808–817. 
 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
14
4.
20
0.
17
.4
0 
- 1
1/
4/
20
13
 1
0:
41
:1
9 
AM
